Professor of Radiology, Brigham and Women's Hospital
Nephrology
Dr. Norman K. Hollenberg, MD
|
|
Give Review
Norman K. Hollenberg, MD works in the field of Nephrology. He has 1 awards "Elected Member". Norman K. Hollenberg is a published doctor as well. He has 85 publications published. The latest was: Maximum renal responses to renin inhibition in healthy study participants: VTP-27999 versus aliskiren.
Publications
- Maximum renal responses to renin inhibition in healthy study participants: VTP-27999 versus aliskiren.
- Habitual flavonoid intake and endothelial function in healthy humans.
- Is there room for dual blockade of the renin-angiotensin-aldosterone system?
- Flavanoids and blood pressure.
- Evaluation of a direct prorenin assay making use of a monoclonal antibody directed against residues 32-39 of the prosegment.
- Varying patterns of the antihypertensive and antialbuminuric response to higher doses of renin-angiotensin-aldosterone system blockade in albuminuric hypertensive type...
- Impact of aliskiren treatment on urinary aldosterone levels in patients with type 2 diabetes and nephropathy: an AVOID substudy.
- Something New to Offer: Renal Denervation.
- Improving Genetic Testing for Gitelman's Syndrome.
- Body Mass and Risk.
- Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy.
- Brain blood flow and velocity: correlations between magnetic resonance imaging and transcranial Doppler sonography.
- Renal plasma flow: glomerular filtration rate relationships in man during direct renin inhibition with aliskiren.
- Cocoa and cardiovascular health.
- Flavanols, the Kuna, cocoa consumption, and nitric oxide.
- Aliskiren accumulates in Renin secretory granules and binds plasma prorenin.
- Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans.
- Is it the dark in dark chocolate?
- Gender and the renal nitric oxide synthase system in healthy humans.
- Renin inhibition: what are the clinical perspectives?
- Insulin induces renal vasodilation, increases plasma renin activity, and sensitizes the renal vasculature to angiotensin receptor blockade in healthy subjects.
- The renin system: is direct renin inhibition different from blockade at the AT1 receptor or the ACE step?
- Prorenin and angiotensin-dependent renal vasoconstriction in type 1 and type 2 diabetes.
- Organ systems dependent on nitric oxide and the potential for nitric oxide-targeted therapies in related diseases.
- Renin angiotensin system blockade and nephropathy: why is it being called into question, and should it be?
- Response to Compliance With Hypertension Therapy: Why Standards Are Needed.
- Recommendations for evaluating compliance and persistence with hypertension therapy using retrospective data.
- The influence of dietary sodium on blood pressure.
- Nonmodulation and essential hypertension.
- Omission of drug dose information.
- (-)-Epicatechin mediates beneficial effects of flavanol-rich cocoa on vascular function in humans.
- Hypertension, the Kuna, and the epidemiology of flavanols.
- Cocoa flavanols and brain perfusion.
- Body mass index and angiotensin-dependent control of the renal circulation in healthy humans.
- Is there a pharmacologic basis for combination renin axis blockade?
- Stress and blood pressure in Kuna Amerinds.
- The road ahead with beta-blockers: expanding treatment options in cardiovascular disease.
- The role of beta-blockers as a cornerstone of cardiovascular therapy.
- Oral contraceptives, angiotensin-dependent renal vasoconstriction, and risk of diabetic nephropathy.
- ACE and non-ACE pathways in the renal vascular response to RAS interruption in type 1 diabetes mellitus.
- Renin inhibition: what are the therapeutic opportunities?
- Lead exposure and chronic renal failure.
- Advanced glycation end-product cross-link breakers. A novel therapeutic pathway for cardiovascular disease.
- Uric acid and the state of the intrarenal renin-angiotensin system in humans.
- Clinical trials report. Asymmetric dimethylarginine, blood pressure, and renal perfusion in elderly subjects.
- Literature alert. Endothelial dilatory function predicts individual susceptibility to renal damage in the 5/6 nephrectomized rats.
- Aldosterone in the development and progression of renal injury.
- Effects of the angiotensin-1 receptor blocker valsartan compared with amlodipine on renal hemodynamics.
- Thyroid function and blood pressure homeostasis in euthyroid subjects.
- Surrogate markers for cardiovascular disease: functional markers.
- Urinary potassium excretion and sodium sensitivity in blacks.
- Plasma aldosterone concentration in the patient with diabetes mellitus.
- Prognostic value of ambulatory blood pressure recordings in patients with treated hypertension.
- Sodium glomerulopathy: tubuloglomerular feedback and renal injury in African Americans.
- Treatment of the patient with diabetes mellitus and risk of nephropathy: what do we know, and what do we need to learn?
- Renal function in the patient with hypertension.
- Considerations for management of fluid dynamic issues associated with thiazolidinediones.
- Genetic determinants of nonmodulating hypertension.
- Urinary albumin excretion predicts cardiovascular and non-cardiovascular mortality in general population.
- Reduction of proteinuria; combined effects of receptor blockade and low dose angiotensin-converting enzyme inhibition.
- Nephron number in patients with primary hypertension.
- Reduced reactivity of renal microvessels to pressure and AngII in fawn-hooded rats.
- Red wine polyphenols enhance endothelial nitric oxide synthase expression and subsequent nitric oxide release from endothelial cells.
- A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia.
- Symptoms and the distress they cause: comparison of an aldosterone antagonist and a calcium channel blocking agent in patients with systolic hypertension.
- The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Major outcomes in high-risk hypertensive patients randomized to angiotensin-c...
- Parallel renal and extremity blood supply abnormalities in nonmodulation: responses to ACE inhibition.
- Pivotal role of the renin/protein receptor in angiotensin II production and cellular responses to renin.
- Dietary sodium and target organ damage in essential hypertension.
- Glomerular hemodynamics and the renin-angiotensin system in patients with type 1 diabetes mellitus.
- A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.
- A genomic-systems biology map for cardiovascular function.
- Defective nitric oxide production and functional renal reserve in patients with type 2 diabetes who have microalbuminuria of African and Asian compared with white origin.
- Vascular abnormalities and elevated blood pressure in mice lacking adrenomedullin gene.
- Renal perfusion in blacks: alterations caused by insuppressibility of intrarenal renin with salt.
- Human hypertension caused by mutations in WNK kinases.
- Characteristics of patients with uncontrolled hypertension in the United States.
- Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100). Comparison with enalapril.
- Renal perfusion and the renal hemodynamic response to blocking the renin system in diabetes: are the forces leading to vasodilation and vasoconstriction linked?
- Genetic versus environmental etiology of the metabolic syndrome among male and female twins.
- Antihypertensive drug therapy in Saskatchewan.
- Angiotensinogen genotype affects renal and adrenal responses to angiotensin II in essential hypertension.
- Familial aggregation of low-renin hypertension.
- When is a Cough Just a Cough? The Issue of Quality of Life and Its Assessment.
Schools
University Of Manitoba Faculty Of Medicine
Doctors Specialties
- Nephrology
Accepted Insurances
Awards
- Elected Member
Education
-
Brigham and Women's Hospital -
University of Manitoba
Hospital
-
Brigham and Women's Hospital
Helpful Reviews
Similar Doctors
|
|
Dr. James A. Strom, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nina Tolkoff-Rubin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nina T. Rubin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Peter G. Linde, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Nathan E. Hellman |
|
|
Dr. Herbert Y. Lin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nelson B. Goes, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Julie M. Paik, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gulvahid G. Shaikh, MD |
|
|
Dr. Kambiz Zandi-Nejad, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Manish R. Maski, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ogo I. Egbuna, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John Danziger, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lesley A. Stevens, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Craig E. Gordon, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nancy P. Wu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Eva B. Long, MD |